{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:34:16Z","timestamp":1793763256143,"version":"4.6.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the utility of adding triamcinolone acetonide to a standard bladder instillation solution for treatment of interstitial cystitis\u2013bladder pain syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>This was a single-center, randomized, double-blind trial that compared symptom response in women with interstitial cystitis\u2013bladder pain syndrome who underwent six bladder instillations with triamcinolone acetonide or six instillations without. All instillation solutions contained heparin, viscous lidocaine, sodium bicarbonate, and bupivacaine. The primary outcome was the change in interstitial cystitis\u2013bladder pain syndrome symptoms from the first to sixth bladder instillation between groups based on the total OLS (O'Leary-Sant Questionnaire) score. Assuming a 4.03-point or larger difference in the mean total OLS score from the first to sixth bladder instillation as compared between the groups, 64 participants were needed to show a significant difference with 80% power at the 0.05 significance level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>From January 2019 to October 2020, 90 women were enrolled\u201445 per group; 71 (79%) completed all six bladder instillations. Randomization resulted in groups with similar characteristics. There was no difference between groups in the primary outcome (bladder instillation with triamcinolone acetonide: mean OLS change \u22126.7 points, 95% CI 4.6\u20138.8 and bladder instillation without triamcinolone acetonide: mean OLS change \u22125.8 points, 95% CI 3.4\u20138.1; <jats:italic toggle=\"yes\">P<\/jats:italic>=.31). Women in both groups had improvement in their interstitial cystitis\u2013bladder pain syndrome symptoms as indicated by a decrease in the total OLS score from the first to sixth bladder instillation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>The addition of triamcinolone acetonide to a standard bladder instillation solution does not improve symptoms associated with interstitial cystitis\u2013bladder pain syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov, NCT03463915.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004348","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T13:40:43Z","timestamp":1617975643000},"page":"810-819","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Bladder Instillations With Triamcinolone Acetonide for Interstitial Cystitis\u2013Bladder Pain Syndrome"],"prefix":"10.1097","volume":"137","author":[{"given":"Olivia O.","family":"Cardenas-Trowers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyce G.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Dotson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke A.","family":"Houlette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy T.","family":"Gaskins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean L.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ju.0000146114.53828.82","article-title":"Prevalence and incidence of interstitial cystitis in a managed care population","volume":"173","author":"Clemens","year":"2005","journal-title":"J Urol"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0025-7125(03)00151-2","article-title":"Interstitial cystitis: a chronic pelvic pain syndrome","volume":"88","author":"Nickel","year":"2004","journal-title":"Med Clin North Am"},{"key":"R4-20250430","article-title":"Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis\/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials","author":"Liu","year":"2020","journal-title":"Int Urogynecol J"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00192-020-04303-7","article-title":"The role of bladder instillation in the treatment of bladder pain syndrome: is intravesical treatment an effective option for patients with bladder pain as well as LUTS?","volume":"31","author":"Digesu","year":"2020","journal-title":"Int Urogynecol J"},{"issue":"5A Suppl","key":"R7-20250430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(99)80333-1","article-title":"The interstitial cystitis symptom index and problem index","volume":"49","author":"O'Leary","year":"1997","journal-title":"Urology"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0090-4295(02)01829-0","article-title":"Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivity","volume":"60","author":"Parsons","year":"2002","journal-title":"Urology"},{"key":"R10-20250430","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"R11-20250430","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1067\/mob.2001.118659","article-title":"Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders","volume":"185","author":"Barber","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/nau.20934","article-title":"Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ)","volume":"30","author":"Barber","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R13-20250430","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00192-012-2020-8","article-title":"A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse\/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)","volume":"24","author":"Rogers","year":"2013","journal-title":"Int Urogynecol J"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R15-20250430","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"6 Suppl 1","key":"R16-20250430","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0090-4295(01)01126-8","article-title":"Psychometric validation of the O'Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium","volume":"57","author":"Lubeck","year":"2001","journal-title":"Urology"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fcimb.2019.00092","article-title":"The vaginal and urinary microbiomes in premenopausal women with interstitial cystitis\/bladder pain syndrome as compared to unaffected controls: a pilot cross-sectional study","volume":"9","author":"Meriwether","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"R19-20250430","first-page":"4536","article-title":"Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner's ulcer subtype interstitial cystitis","volume":"16","author":"Cox","year":"2009","journal-title":"Can J Urol"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12894-020-00597-3","article-title":"Clinical efficacy of submucosal injection of triamcinolone acetonide in the treatment of type II\/III interstitial cystitis\/bladder pain syndrome","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Urol"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00192-017-3266-y","article-title":"Which bladder instillations are more effective? DMSO vs. bupivacaine\/heparin\/triamcinolone: a retrospective study","volume":"28","author":"Iyer","year":"2017","journal-title":"Int Urogynecol J"},{"key":"R22-20250430","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00192-012-1832-x","article-title":"Measuring the success of combined intravesical dimethyl sulfoxide and triamcinolone for treatment of bladder pain syndrome\/interstitial cystitis","volume":"24","author":"Gafni-Kane","year":"2013","journal-title":"Int Urogynecol J"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00192-016-3232-0","article-title":"Long-term outcomes of intravesical dimethyl sulfoxide\/heparin\/hydrocortisone therapy for interstitial cystitis\/bladder pain syndrome","volume":"28","author":"Lim","year":"2017","journal-title":"Int Urogynecol J"},{"key":"R25-20250430","first-page":"629","article-title":"Review of intravesical therapies for bladder pain syndrome\/interstitial cystitis","volume":"4","author":"Cvach","year":"2015","journal-title":"Transl Androl Urol"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"868","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00011","article-title":"A review of the evidence for overlap among unexplained clinical conditions","volume":"134","author":"Aaron","year":"2001","journal-title":"Ann Intern Med"},{"issue":"1 Suppl","key":"R27-20250430","first-page":"S66","article-title":"Evidence for overlap between urological and nonurological unexplained clinical conditions","volume":"189","author":"Bullones Rodr\u00edguez","year":"2013","journal-title":"J Urol"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2007.02.067","article-title":"Prevalence of pelvic floor dysfunction in patients with interstitial cystitis","volume":"70","author":"Peters","year":"2007","journal-title":"Urology"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1097\/JU.0000000000001237","article-title":"High-density surface electromyography assessment of pelvic floor dysfunction in women with interstitial cystitis\/bladder pain syndrome","volume":"204","author":"Dias","year":"2020","journal-title":"J Urol"},{"key":"R30-20250430","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.juro.2012.01.123","article-title":"Interstitial Cystitis Collaborative Research Network, Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis\/painful bladder syndrome and pelvic floor tenderness","volume":"187","author":"FitzGerald","year":"2012","journal-title":"J Urol"},{"key":"R33-20250430","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.juro.2009.12.106","article-title":"Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment na\u00efve patients with interstitial cystitis\/painful bladder syndrome","volume":"183","author":"Foster","year":"2010","journal-title":"J Urol"},{"key":"R34-20250430","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/01.ju.0000083020.06212.3d","article-title":"Interstitial Cystitis Clinical Trials Group, A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis","volume":"170","author":"Sant","year":"2003","journal-title":"J Urol"},{"key":"R35-20250430","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.urology.2014.04.011","article-title":"Examination of the significant placebo effect in the treatment of interstitial cystitis\/bladder pain syndrome","volume":"84","author":"Bosch","year":"2014","journal-title":"Urology"},{"key":"R38-20250430","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/nau.23467","article-title":"Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients","volume":"37","author":"Akiyama","year":"2018","journal-title":"Neurourol Urodyn"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:50:37Z","timestamp":1746082237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004348"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004348","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"2020-12-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}